Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

NEXT STORY
Orion has been notified by the largest shareholders by votes that at the AGM to be held on 6 May 2020 they will support the proposals that are in the notice to the AGM
PREV STORY
Roche develops new serology test to detect COVID-19 antibodies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global DNA Damage Response Targeting Therapeutics Market Report 2021: Current Landscape and the Likely Adoption of DNA Damage Response Targeting Therapeutics in Healthcare Over the Next Decade

author_avatar
NASDAQ Market News

Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering

MADISON, Wis., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("Cellectar" or ...

author_avatar
NASDAQ Market News

Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2017 Financial Results, Business Progress Against Plan and Recent Accomplishments

Revenue for the Quarter Grew 40% over the Comparable Prior Year Quarter and 21% for ...

author_avatar
NASDAQ Market News